Montelukast – Asthma management medicine that assures correct dosage and is patient friendly

Asthma is a chronic inflammatory condition of the airwaves which leads to bronchoconstriction that can be alleviated with a reliever inhaler such as a beta agonist. Although allergens such as pollen, dust as well as pollution and infection have been identified as attack triggers, however many cases remain without any prominent cause. One of the primary aims of asthma is to manage symptoms and attacks in order to prevent hospitalisation which leads to high health care expenditure costs, without ignoring the priority of the patient’s quality of life.

Inhalation remedies are generally the preferred route of therapy, based on a patient’s “step” ranking as described per the Global Initiative for Asthma (GINA). However, patient demonstration of correct inhaler technique is frequently suboptimal, as well as a huge issue arising around patient counseling. A recent report in the Annals of Allergy, Asthma and Immunotherapy found that as low as 7 % of patients prescribed an inhaler were shown how to use the device correctly by a healthcare professional^[1]. Other issues lie around inhaler use, such as with children and patients with dexterity issues such as rheumatoid arthritis, which require inhaler aids which often incorporate a significant increase in cost to therapy.

Montelukast belongs to a group of medicines called leukotriene agonists, which are orally active and are thus available in tablet form, with chewable tablets for children. This ensures a correct dose as well as patient acceptability which aims to increase drug adherence. Montelukast acts as an inhibitor to leukotrienes acting on their receptors. Leukotrienes are inflammatory mediators which have been shown to cause bronchoconstriction as well as oedema, and thus their suppression can lead to a therapeutic effect in asthma patients. Although not first line treatment, montelukast is seen to have beneficial effects when partnered with inhaled corticosteroid therapy with asthmatic patients, as well as recommended as a good option in the management of exercise induced asthma and rhinitis by the British National Formulary, as of February 2015. Recent studies have also linked montelukast as a potential target compound for the likes alzheimers’ disease which is characterised by the build-up of amyloid plaques in vivo. Montelukast antagonises cysteinyl leukotriene receptors, which are unregulated in the presence of amyloid beta which progresses to amyloid fibrils. In vitro analyses showed a down regulation in inflammatory mediators, the levels of cysteinyl leukotrienes as well as protecting against neuronal apoptosis and neurotoxicity.

Montelukast is available in either 5 mg tablet or 4 mg chewable tablet formulation by Taj Accura Pharmaceuticals, a specialist in international manufacturing & wholesaling of quality pharmaceutical goods.

1. Bonds R.S, Asawa A, Ghazi A.I. Misuse of medical devices: a persistent problem in self-management of asthma and allergic disease. Annals of Allergy, Asthma & Immunology, Vol. 114, Issue 1, p74–76Montelukast – Asthma management medicine that assures correct dosage and is patient friendly – Taj Dearob Pharma | Asthma is a chronic inflammatory condition of the airwaves which leads to bronchoconstriction that can be alleviated with a reliever inhaler such as a beta agonist. Although allergens such as pollen, dust as well as pollution and infection have been identified as attack triggers, however many cases remain without any prominent cause. One of the primary aims of asthma is to manage symptoms and attacks in order to prevent hospitalisation which leads to high health care expenditure costs, without ignoring the priority of the patient’s quality of life.
Montelukast – Asthma management medicine that assures correct dosage and is patient friendly – Taj Dearob Pharma | Asthma is a chronic inflammatory condition of the airwaves which leads to bronchoconstriction that can be alleviated with a reliever inhaler such as a beta agonist. Although allergens such as pollen, dust as well as pollution and infection have been identified as attack triggers, however many cases remain without any prominent cause. One of the primary aims of asthma is to manage symptoms and attacks in order to prevent hospitalisation which leads to high health care expenditure costs, without ignoring the priority of the patient’s quality of life.
Montelukast – Asthma management medicine that assures correct dosage and is patient friendly – Taj Dearob Pharma | Asthma is a chronic inflammatory condition of the airwaves which leads to bronchoconstriction that can be alleviated with a reliever inhaler such as a beta agonist. Although allergens such as pollen, dust as well as pollution and infection have been identified as attack triggers, however many cases remain without any prominent cause. One of the primary aims of asthma is to manage symptoms and attacks in order to prevent hospitalisation which leads to high health care expenditure costs, without ignoring the priority of the patient’s quality of life.
Montelukast – Asthma management medicine that assures correct dosage and is patient friendly – Taj Dearob Pharma | Asthma is a chronic inflammatory condition of the airwaves which leads to bronchoconstriction that can be alleviated with a reliever inhaler such as a beta agonist. Although allergens such as pollen, dust as well as pollution and infection have been identified as attack triggers, however many cases remain without any prominent cause. One of the primary aims of asthma is to manage symptoms and attacks in order to prevent hospitalisation which leads to high health care expenditure costs, without ignoring the priority of the patient’s quality of life.